UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

 

 

 

 

 

 

 

FORM 12b-25

 

 

NOTIFICATION OF LATE FILING

 


 

(Check one):

X

 Form 10-K 

 

 Form 20-F 

 

 Form 11-K 

 

 Form 10-Q 

 

 Form 10-D 

 

 Form N-SAR 

 

 Form N-CSR

 

 

For Period Ended:

September 30, 2008

 

 

 

 

 

 Transition Report on Form 10-K

 

 

 

 

 

 Transition Report on Form 20-F

 

 

 

 

 

 Transition Report on Form 11-K

 

 

 

 

 

 Transition Report on Form 10-Q

 

 

 

 

 

 Transition Report on Form N-SAR

 

 

 

 

For the Transition Period Ended:

 

 

 

 


Read Instructions (on back page) Before Preparing Form. Please Print or Type.

 

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

 

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

 


PART I — REGISTRANT INFORMATION


 

Med Gen, Inc.

Full Name of Registrant

 

 

Former Name if Applicable

 

7280 W. Palmetto Park Road, Suite 306

Address of Principal Executive Office (Street and Number)

 

Boca Raton, FL 33433

City, State and Zip Code


 

PART II — RULES 12b25(b) AND (c)

 

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b25(b), the following should be completed. (Check box if appropriate)


 

 

 

 

 

 

 

 

  (a)

The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;

 

  (b)

The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D,or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and

X

 

 

  (c)

The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.






 

PART III — NARRATIVE

 

State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period. (Attach extra Sheets if Needed)

 

 

The Auditor is still in the process of completing his audit of the Company’s financials for the fiscal year ended September 30, 2008.  The Registrant anticipates completion and filing of it’s Form 10-K for the fiscal year ended September 30, 2008 within the time period provided by this extension.

 

 

PART IV — OTHER INFORMATION


 

 

 

 

 

 

 

 

 

 

(1)

Name and telephone number of person to contact in regard to this notification

 

 

Paul Kravitz

 

 (561)

 

 750-1100

 

(Name)

 

(Area Code)

 

(Telephone Number)

 

(2)

Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).

Yes 

X

No 

 

 

 

 

 

(3)

Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

Yes 

 

No 

X

 

 

 

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

 


 

 

 

 

 

Med Gen, Inc .

 

(Name of Registrant as Specified in Charter)

 

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date:

December 30, 2008

 

By:

/s/ Paul Kravitz

 

 

 

 

 Paul Kravitz, Chief Executive Officer





MedGen (CE) (USOTC:MDIN)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024 Click aqui para mais gráficos MedGen (CE).
MedGen (CE) (USOTC:MDIN)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024 Click aqui para mais gráficos MedGen (CE).